HbA1c to Average Glucose Converter
Convert glycated haemoglobin (HbA1c) to estimated average glucose (eAG) in mg/dL or mmol/L. Includes IFCC unit conversion and clinical interpretation for diabetes screening and monitoring.
Calculate Estimated Average Glucose
Enter the patient’s HbA1c value to calculate the estimated average glucose (eAG). This converter uses the ADAG study formula and supports both NGSP (%) and IFCC (mmol/mol) input formats.
The eAG is a population-level estimate derived from the ADAG study. Individual average glucose may differ from eAG by ±15 mg/dL (±0.8 mmol/L). Conditions that alter red blood cell turnover — such as haemoglobinopathies, anaemia, or recent transfusion — may render HbA1c unreliable.
Understanding HbA1c & Estimated Average Glucose
Glycated haemoglobin (HbA1c) measures the proportion of haemoglobin that has undergone non-enzymatic glycation — a process in which glucose molecules irreversibly attach to the N-terminal valine of the haemoglobin beta chain. Because red blood cells have an average lifespan of approximately 120 days, HbA1c reflects the weighted average blood glucose over the preceding 2–3 months, with greater emphasis on the most recent 30 days (approximately 50% of the HbA1c value).
The concept of estimated average glucose (eAG) was developed through the ADAG (A1c-Derived Average Glucose) study published by Nathan et al. in 2008. This landmark study established a linear relationship between HbA1c and mean glucose by using continuous glucose monitoring (CGM) and frequent self-monitoring in 507 participants across 10 international centres.
eAG Formula (mg/dL)
eAG = 28.7 × HbA1c − 46.7
Example: HbA1c of 7.0% → eAG = 28.7 × 7.0 − 46.7 = 154.2 mg/dL
eAG Formula (mmol/L)
eAG = 1.59 × HbA1c − 2.59
Example: HbA1c of 7.0% → eAG = 1.59 × 7.0 − 2.59 = 8.6 mmol/L
NGSP vs IFCC units: Most of the world reports HbA1c as a percentage (NGSP standard). The IFCC method reports in mmol/mol. The conversion is: IFCC = (NGSP − 2.15) × 10.929. Both are accepted internationally, but clinicians must know which system their laboratory uses. An HbA1c of 6.5% (NGSP) equals 48 mmol/mol (IFCC).
HbA1c Interpretation & Diagnostic Thresholds
The following table shows the ADA/WHO diagnostic thresholds for diabetes and prediabetes based on HbA1c, along with corresponding estimated average glucose values. These thresholds are intended for screening and diagnosis in non-pregnant adults.
| Category | HbA1c (NGSP) | HbA1c (IFCC) | eAG (mg/dL) | eAG (mmol/L) |
|---|---|---|---|---|
| Normal | < 5.7% | < 39 mmol/mol | < 117 | < 6.5 |
| Prediabetes | 5.7 – 6.4% | 39 – 47 mmol/mol | 117 – 137 | 6.5 – 7.6 |
| Diabetes | ≥ 6.5% | ≥ 48 mmol/mol | ≥ 140 | ≥ 7.8 |
| Poorly Controlled | > 9.0% | > 75 mmol/mol | > 212 | > 11.8 |
The ADA recommends a target HbA1c of < 7.0% (eAG < 154 mg/dL) for most non-pregnant adults with diabetes. However, targets should be individualised — a less stringent goal of < 8.0% may be appropriate for older patients or those with significant comorbidities, while more stringent targets (< 6.5%) may be considered in select patients with short disease duration and no significant cardiovascular disease, if achievable without significant hypoglycaemia.
Common HbA1c-to-eAG Reference Values
| HbA1c (%) | IFCC (mmol/mol) | eAG (mg/dL) | eAG (mmol/L) |
|---|---|---|---|
| 5.0 | 31 | 97 | 5.4 |
| 5.5 | 37 | 111 | 6.2 |
| 6.0 | 42 | 126 | 7.0 |
| 6.5 | 48 | 140 | 7.8 |
| 7.0 | 53 | 154 | 8.6 |
| 7.5 | 58 | 169 | 9.4 |
| 8.0 | 64 | 183 | 10.2 |
| 8.5 | 69 | 197 | 10.9 |
| 9.0 | 75 | 212 | 11.8 |
| 10.0 | 86 | 240 | 13.4 |
| 11.0 | 97 | 269 | 14.9 |
| 12.0 | 108 | 298 | 16.5 |
Factors Affecting HbA1c Accuracy
HbA1c is a reliable marker for most patients but can be falsely elevated or reduced in certain conditions. Understanding these factors is essential for correct clinical interpretation.
Several conditions can cause HbA1c to overestimate true average glucose. Iron deficiency anaemia is among the most common culprits — reduced red cell turnover leads to older, more glycated haemoglobin predominating, pushing HbA1c upward by 0.5–1.0% even in non-diabetic patients. Similarly, vitamin B12 and folate deficiency can cause megaloblastic changes with a similar effect.
Chronic kidney disease (CKD stages 4–5) is associated with carbamylated haemoglobin, which interferes with some HbA1c assays and produces falsely high readings. Splenectomy prolongs red cell lifespan, allowing more glycation time and overestimating average glucose. High-dose aspirin therapy and chronic alcohol use have also been reported to elevate HbA1c through assay interference.
- Iron deficiency anaemia (most common cause)
- Vitamin B12 / folate deficiency
- Splenectomy or functional asplenia
- Chronic kidney disease (uraemia, carbamylation)
- Hypertriglyceridaemia (assay interference)
Anything that accelerates red blood cell turnover or shortens erythrocyte lifespan will reduce the time available for glycation, producing a falsely low HbA1c. Haemolytic anaemias — whether autoimmune, mechanical (prosthetic valves), or due to haemoglobinopathies — are the classic example. Patients with sickle cell disease (HbSS, HbSC) often have HbA1c values that dramatically underestimate their true glycaemic burden.
Recent blood loss or transfusion dilutes glycated haemoglobin with fresh, unglycated red cells. Erythropoietin therapy (e.g., in CKD patients on dialysis) stimulates new red cell production, similarly lowering HbA1c. Pregnancy — particularly the second and third trimesters — increases red cell mass and plasma volume, producing haemodilution that lowers HbA1c by approximately 0.5%.
- Haemolytic anaemias (autoimmune, mechanical, hereditary)
- Haemoglobinopathies (HbS, HbC, HbE — assay-dependent)
- Blood loss, recent transfusion
- Erythropoietin therapy
- Pregnancy (2nd and 3rd trimesters)
- Chronic liver disease (cirrhosis)
Haemoglobin variants such as HbS, HbC, HbD, and HbE can interfere with certain HbA1c assay methods, producing either falsely high or falsely low results depending on the specific variant and the assay platform used. HPLC-based methods are particularly susceptible to interference from haemoglobin variants, whereas immunoassay and boronate affinity methods are generally less affected but not immune.
For patients with known haemoglobinopathies, clinicians should verify which assay method their laboratory uses and whether it is validated for use with the specific variant present. Alternative markers such as fructosamine (reflecting average glucose over 2–3 weeks) or glycated albumin may be more reliable in these populations. The NGSP maintains a regularly updated list of assay interference at ngsp.org/interf.asp.
A critical limitation of HbA1c — and by extension eAG — is that it represents an average and provides no information about glycaemic variability. Two patients with identical HbA1c values of 7.0% (eAG ~154 mg/dL) may have very different glucose profiles: one may have stable glucose levels between 120–180 mg/dL, while the other may oscillate between hypoglycaemic episodes below 54 mg/dL and hyperglycaemic spikes above 300 mg/dL.
Growing evidence suggests that glycaemic variability is an independent risk factor for diabetes complications, particularly cardiovascular events and oxidative stress. For this reason, continuous glucose monitoring (CGM) metrics — including time in range (TIR), coefficient of variation (CV), and time below range (TBR) — are increasingly used alongside HbA1c to provide a more complete picture of glycaemic control. The international consensus recommends TIR > 70% (glucose 70–180 mg/dL) as a therapeutic target.
Research has consistently demonstrated that HbA1c levels differ between racial and ethnic groups even after adjusting for measured glucose levels. Studies show that Black, Hispanic, and Asian individuals tend to have HbA1c values approximately 0.2–0.4% higher than White individuals with the same average glucose. This discrepancy may be driven by differences in red blood cell membrane properties, haemoglobin glycation rates, or erythrocyte lifespan rather than by true differences in glycaemia.
These population-level differences have implications for diabetes screening and diagnosis when using HbA1c alone. Using the standard 6.5% diagnostic threshold may miss diabetes in some populations while over-diagnosing in others. Clinicians should consider confirmatory testing with fasting plasma glucose or OGTT when there is clinical suspicion of diabetes but the HbA1c result seems discordant with other findings.
When HbA1c seems discordant with point-of-care glucose readings or patient-reported values, consider: (1) altered red cell turnover, (2) haemoglobin variant interference, (3) recent blood loss or transfusion, or (4) significant glycaemic variability masked by the average. In these situations, fructosamine, glycated albumin, or CGM data may provide a more accurate assessment.
Common Pitfalls & Limitations
While HbA1c ≥ 6.5% is accepted as a diagnostic threshold for type 2 diabetes, it should not be used in isolation — particularly in populations where its accuracy is questioned. The ADA recommends confirming the diagnosis with a repeat HbA1c or an alternative test (fasting glucose, OGTT) unless the patient has classic hyperglycaemic symptoms with a random glucose ≥ 200 mg/dL. In patients with conditions affecting red cell turnover (anaemia, haemoglobinopathies, pregnancy), fasting glucose or OGTT should be used instead of HbA1c.
Clinical consequence: Relying solely on HbA1c may lead to missed diagnoses in patients with falsely low readings (e.g., haemolytic states) or overdiagnosis in those with falsely elevated values (e.g., iron deficiency).
The two HbA1c reporting systems — NGSP (percentage) and IFCC (mmol/mol) — can cause significant confusion. An HbA1c of “48” means very different things depending on the unit system: 48 mmol/mol (IFCC) equates to 6.5% (NGSP, diagnostic threshold for diabetes), whereas an HbA1c of 48% would be an impossibly high value. Errors in unit interpretation have been documented in clinical practice, particularly when patients move between healthcare systems that use different standards.
How to avoid: Always check which unit system the laboratory uses. Many countries (including much of Europe, Australia, and Japan) have adopted IFCC reporting. The United States and much of the Middle East continue to use NGSP. Some laboratories now report both values side by side.
The eAG formula provides a population-level estimate based on the regression equation from the ADAG study. Individual variation around this estimate is substantial — the 95% confidence interval for an HbA1c of 7.0% ranges from approximately 123 to 185 mg/dL (6.8 to 10.3 mmol/L). This means that two patients with the same HbA1c may have meaningfully different actual average glucose levels.
Biological factors that contribute to this inter-individual variability include differences in haemoglobin glycation rates, red cell lifespan, and the relative contribution of fasting versus postprandial glucose. Communicating eAG to patients is useful for translating HbA1c into more intuitive units, but clinicians should explain that it is an estimate and that CGM data or frequent self-monitoring provides a more personalised picture.
HbA1c is often described as reflecting average glucose over “the past 2–3 months,” but this description oversimplifies the kinetics. The contribution is time-weighted: the most recent 30 days contribute approximately 50% of the HbA1c value, days 30–60 contribute about 25%, and days 60–120 contribute the remaining 25%. This means a dramatic improvement or deterioration in glycaemic control over the past month will be partially reflected in the current HbA1c, even though the full effect takes 2–3 months to manifest.
Clinical consequence: Checking HbA1c too soon after a medication change (e.g., at 4 weeks) will underestimate the true impact. The ADA recommends rechecking HbA1c at 3-month intervals after treatment adjustments. Conversely, a sudden improvement in HbA1c may reflect only recent changes rather than sustained control.
Point-of-care (POC) HbA1c devices are increasingly used in primary care for their convenience, but they may have wider analytical imprecision compared to laboratory-based methods. The NGSP certification programme certifies POC devices, but performance can vary between manufacturers and even between individual devices. Most POC methods have a coefficient of variation (CV) of 3–5% compared to < 2% for laboratory methods.
For screening and monitoring in stable patients, POC testing is generally acceptable. However, for diagnostic decisions at key thresholds (e.g., 6.5% for diabetes diagnosis), laboratory confirmation is recommended. Additionally, POC devices may be more susceptible to interference from haemoglobin variants, extreme temperatures, and sample quality issues such as insufficient capillary blood volume.
Quick Reference Summary
(eAG < 117 mg/dL)
(eAG 117–137 mg/dL)
(eAG ≥ 140 mg/dL)
(eAG < 154 mg/dL)
| Clinical Decision Point | HbA1c Threshold | Action |
|---|---|---|
| Diabetes screening positive | ≥ 6.5% | Confirm with repeat test or fasting glucose/OGTT |
| Prediabetes identification | 5.7–6.4% | Lifestyle modification, consider metformin if high risk |
| At target (most adults) | < 7.0% | Continue current regimen, recheck in 3–6 months |
| Above target | ≥ 7.0% | Intensify therapy, recheck in 3 months |
| Poorly controlled | > 9.0% | Consider combination/injectable therapy, assess adherence |
The Golden Rule: HbA1c is a powerful monitoring tool, but it is an average — it cannot distinguish stable euglycaemia from wild swings between hypoglycaemia and hyperglycaemia. Always interpret HbA1c alongside self-monitored blood glucose logs, CGM data where available, and the overall clinical picture.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-1478. DOI: 10.2337/dc08-0545
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. DOI: 10.2337/dc24-S002
- Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011;34(6):e61-e99. DOI: 10.2337/dc11-9998
- Bergenstal RM, Gal RL, Connor CG, et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med. 2017;167(2):95-102. DOI: 10.7326/M16-2596
- Welsh KJ, Kirkman MS, Sacks DB. Role of glycated proteins in the diagnosis and management of diabetes: research gaps and future directions. Diabetes Care. 2016;39(8):1299-1306. DOI: 10.2337/dc15-2727
- Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. DOI: 10.2337/dci19-0028
- Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29(2):388-394. DOI: 10.1007/s11606-013-2595-x
- World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. WHO/NMH/CHP/CPM/11.1. 2011. Available at: who.int